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Abstract 
The LRRK2 gene (Leucine-Rich Repeat Kinase 2, PARK8) is mutated in a significant number of cases of 
autosomal dominant Parkinson's disease (PD) and in some sporadic cases of late-onset PD. LRRK2 is a 
large, complex protein that comprises several interaction domains: armadillo, ankyrin, leucine-rich 
repeats and WD40 domains; two catalytic domains: ROC-GTPase and serine/threonine kinase; and a 
COR domain (unknown function). Pathogenic mutations are scattered all over the domains of LRRK2, 
although the prevalence of mutations in some domains is higher (ROC-GTPase, COR and kinase). In this 
work, we model the structure of each domain to predict and explore the effects of described missense 
mutations and polymorphisms. The results allow us to postulate the possible effects of pathogenic 
mutations in the function of the protein, and hypothesize the importance of some polymorphisms that 
have not been linked directly to PD, but act as risk factors for the disease. In our analysis, we also study 
the effects of PD-related mutations in the kinase domain structure and in the phosphorylation of the 
activation loop to determine effects on kinase activity. 
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Introduction 
Parkinson's disease (PD) is a neurodegenerative disorder caused by genetic and environmental 
factors. Clinic features are resting tremor, bradykinesia, rigidity and postural instability, caused by the 
progressive loss of dopaminergic neurons in the substantia nigra of the central nervous system (CNS). 
 To date, 15 loci associated with the appearance of several variants of the disease have been 
identified [1]. In 2004, our group identified mutations in the LRRK2 gene (Leucine-Rich Repeat Kinase 2, 
PARK8, MIM# 607060) as being responsible for some forms of PD [2]. Its gene product (dardarin or 
LRRK2) is a multidomain protein of 2527 amino acids, with an approximate molecular weight of 280 
kDa. The function of this protein is not fully known, although several studies have indicated a role in 
vesicle traffic, cytoskeleton dynamics, signal transduction, translation regulation, apoptosis, oxidative 
stress response and mitochondrial function. Furthermore, there is evidence to suggest a common pathway 
with α-synuclein (MIM#163890), parkin (MIM# 602544) and TAU (MIM# 157140) in PD [1]. Today it 
is considered that some specific mutations (e.g., p.R1441G/C or p.G2019S) are a major cause of the 
disease since they are responsible for approximately 2-4% of cases in Caucasian populations [3]. The 
phenotype associated with these mutations is late-onset PD, commonly indistinguishable from the 
idiopathic disease. Moreover, the neuropathology associated with LRRK2 mutations is variable, 
suggesting that this protein is involved in several pathways. Dardarin-associated PD causes loss of 
dopaminergic neurons and sometimes abnormal accumulation of ubiquitinated proteins, mainly α-
synuclein and occasionally hyperphosphorylated tau [4]. 
LRRK2 comprises several independent domains, some of which are typically involved in 
protein-protein interaction: armadillo (ARM), ankyrin (ANK), leucine-rich repeats (LRR) and WD40 
domains. The N-terminal region of LRRK2 contains seven ankyrin-type repeats that form the ANK 
domain. In addition, 13 leucine-rich repeats (LRR) have also been identified in this region. This domain 
participates in interactions with other proteins through the extensive surface with accessibity to the 
solvent. There have also been predicted C-terminal repeats that form a WD40 domain [5]. The presence 
or absence of the armadillo domain in the N-terminal has been a controversial matter, but recent studies 
conclude that LRRK2 contains armadillo-type repeats (ARM-like) [6]. Moreover, LRRK2 encodes two 
enzymatic activities: kinase and GTPase. The GTPase domain belongs to the ROCO family, with the 
GTPase typically in tandem with a COR domain. The ROC-COR (ROCO) module is conserved 
throughout evolution, suggesting the functional interdependence of the two domains [6]. Activation of the 
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kinase domain (KIN) probably occurs by phosphorylation in a sequence of 25-30 amino acids loop that is 
flanked by conserved motifs DF/YG and APE, whose conformation changes to allow access to the 
substrate [5]. These conformation changes may be mediated by molecular interactions such as hydrogen 
bonds [7].  
Some authors have proposed that LRRK2 predominantly forms a dimer in vivo that autoregulates 
itself by phosphorylation, and it seems that dimerization takes place through several LRRK2 regions, but 
the exact parts involved in this phenomenon remain unclear [8]. Some authors postulate that the ROCO 
domain is critical, but not exclusive, to dimerization [9]. Although other proteins of the ROCO family 
form dimers through COR-COR interactions [10], these interactions were not observed in LRRK2, and 
there is evidence for ROC-ROC interactions obtained from three-dimensional structures [11]. This model 
suggests that residues R1441 and I1371, associated with PD, are located on the dimerization surface and 
stabilize the dimer. 
At least 20 mutations linked to autosomal dominant PD, and approximately the same number for 
sporadic PD, have been described. Mutations in LRRK2 are the most common genetic cause of autosomal 
dominant PD, especially in certain populations [12]. The p.G2019S mutation has been detected in 5-6% 
of familial PD, and in 1-2% of sporadic cases. This prevalence can be higher in specific populations such 
as Ashkenazi Jews and Arabs from North Africa. Dardarin mutations are found mostly at the C-terminal 
half, suggesting that it is more important at a functional level. However, some are also found in the N-
terminal region along the ARM, ANK and LRR domains, and some authors have postulated that 
mutations in these domains can interfere, similarly to those in WD40, with the binding to other proteins or 
molecules [5]. The most studied mutations are those found in catalytic domains. p.G2019S gives rise to a 
hyperactive kinase, increasing autophosphorylation and phosphorylation of generic substrates [13]. Other 
mutations commonly found in patients with PD, such as p.R1441G/C, which affects the GTPase domain, 
appear to reduce this activity, but enhance kinase activity [4], whereas the p.R1441H mutation inhibits 
this activity. In the WD40 domain, the p.G2385R mutation has also been described as attenuating kinase 
activity [14]. There have also been reports that pathogenic mutations p.R1441C, p.Y1699C or p.G2019S 
cause neuronal degeneration, protein aggregates or intracytoplasmatic inclusions in cultured neural cells 
[15], as well as increased apoptosis [16]. In general, the overexpression of mutant LRRK2 causes loss of 
viability, whereas inactivation of the kinase reduces this toxicity [15]. However, the influence of different 
amino acid substitutions in protein kinase activity is controversial, and the mechanisms by which dardarin 
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mutations cause PD appear to be complex and cannot be explained only by kinase activity. In this work, 
we intend to provide new evidence for and an appropriate framework to determine the pathogenicity of 
the genetic variants in dardarin by performing an in silico analysis of the variants described as pathogenic 
or polymorphic. 
Methods 
The tertiary structure models were performed by sequence homology using EasyModeller [17] 
with default settings for the LRR, COR and KIN domains, for which a suitable template was found. The 
rest of the domains were modeled by threading for the LOMETS meta-server 
(http://zhanglab.ccmb.med.umich.edu/LOMETS/) with default settings, and by the best model obtained, 
based on the z-score and the absence of unfolded areas. The alignments of the templates and the LRRK2 
sequences, as well as the percentage of similarity and threading parameters, are shown in Suppl. Fig. 1. A 
Mutational analysis was performed, as previously described [18], for the missense substitutions described 
in these domains according to the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk). To view 
and edit the structures, we used the PyMOL software (DeLano Scientific Inc). The structures obtained for 
each wild-type domain were deposited in the Protein Model Database (http://mi.caspur.it/PMDB/). For 
the phosphorylation motif analysis, we used GPS 2.1 (http://gps.biocuckoo.org/online.php) and 
NetPhos/NetPhosK (http://www.cbs.dtu.dk/services/NetPhos/ ; 
http://www.cbs.dtu.dk/services/NetPhosK/). For the analysis of stability and function/pathogenicity 
alterations, several methods were used [19-27] and the results are provided in Suppl. Table 1 and Suppl. 
Table 2. Those results that were coincident in at least 75% of the analyses were accepted. 
Results 
To predict the structural effects of the PD-related mutations, the structure of each LRRK2 
domain and the possible alteration caused by each missense mutation were analyzed in silico. Previously, 
as some domain definition, and even the presence or absence of the ARM domain, is controversial [5-6], 
we also carried out a redefinition of the domain boundaries based on the predicted, or previously 
resolved, tertiary structures. The results obtained (Fig. 1) indicate the presence of the ARM domain, and 
also some differences from other works [5] in a given domain definition. So the COR and KIN domains 
were 54 and 8 amino acids smaller than expected, respectively, whereas the LRR and ROC domains were 
respectively 5 amino acids bigger than previously described.  
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Afterward, we predicted the effect of the missense mutations related to PD (Fig. 2) in secondary 
and tertiary structures, on the electrostatic surface, in polar contacts and charge distribution, as well as 
stability, function alteration and possible pathogenicity. 
ARM domain 
According to the model obtained (Suppl. Fig. 2a), this domain is formed by 21 α-helices 
grouped into threes to form supercoils and are linked by loops to form a curved structure where loops 
were more exposed to the solvent. The tertiary structure prediction was made by threading, and the best 
model obtained was selected by using the α-importin of Saccharomyces cerevisiae as a template (PDB ID 
1wa5B). This domain contains three described amino acid substitutions: p.A211V, p.E334K and 
p.N363S. Whereas no significant change was observed for the p.A211V substitution, the results show that 
the p.E334K mutation, described as PD-associated, affected the electrostatic surface and charge 
distribution in this domain (Suppl. Fig. 2a). The p.N363S mutation determined the loss of two hydrogen 
bonds with H365 and V366, which were in an α-helix near a loop (Suppl. Fig. 2a), and which may affect 
its flexibility and stability (Table 1). This amino acid substitution also generated a target motif for 
PRKG1 (Fig. 3a), which performs important functions in nervous system development and regulation, 
and has been related with axon branching and neurite elongation [28]. 
ANK domain 
 This domain is formed by 11 α-helices linked by loops that are more exposed to the solvent 
(Suppl. Fig. 2b). The three-dimensional model of this domain was run by threading using the human 
gankyrin (PDB ID 1uohA) as a template. In this domain, four substitutions, p.M712V, p.P755L, p.R793M 
and p.I810V, are described. Of those, p.M712V and p.I810V were not clearly associated with PD [29]. 
Nevertheless, and as seen in Table 1 and Suppl. Fig. 2b, the p.M712V model showed that this mutation 
would affect both protein stability and the electrostatic surface. Moreover, p.P755L and p.R793M were 
described as being PD-related. The former affects protein stability (Table 1), whereas the latter alters the 
function, charge distribution and electrostatic surface (Table 1 and Suppl. Fig. 2b). These effects noted 
on the electrostatic surface have been previously predicted by other authors [30].  
LRR domain 
The tertiary structure of this domain (Suppl. Fig. 3) was modeled by homology using Lingo1 as 
a template (PDB ID 2id5C). The model shows that this domain is composed of 13 parallel β-sheets linked 
by large loops to form a curved structure that is highly exposed to the solvent.  Similar results have been 
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previously described for this domain [31]. Eight amino acids substitutions were described along this 
domain, four of which were considered to be pathogenic: p.Q1111H, p.I1122V, p.I1192V and p.S1228T. 
The p.R1067Q polymorphism caused the loss of a positive charge, the alteration of the electronic surface 
and it altered domain stability (Suppl. Fig. 3). The effects of this mutation on the surface charge have 
been previously hinted at by other authors [30-31]. Otherwise, p.Q1111H, p.I1122V and p.S1228T 
affected the stability of the domain, p.L1165P altered the function of the protein (Table 1) and p.A1151T 
caused the appearance of a hydrogen bond with p.K1129 (Suppl. Fig. 3), belonging to a near loop, which 
could imply increased rigidity between these loops. p.R1067Q, p.Q1111H, p.I1122V, p.I1192V and 
p.S1228T have been previously predicted as being localized at the hydrophobic core of the domain, and 
could affect interaction with other proteins, but without affecting the structure [31]. 
Pathogenic mutation p.S1228T introduced a motif for MAP3K7 (Fig. 3a), which is involved in 
neurite outgrowth and neuronal death [32]. This variant also affected the distribution of the hydrogen 
bonds (Suppl. Fig. 3), so p.S1228 formed hydrogen bonds with S1203, N1230 and S1250, while p.T1228 
did so only with S1203 and N1230, which could weaken that with the loop, which contains S1250. 
Substitution p.H1216R implied a gain of a positive charge on the domain surface (Table 1 and Suppl. 
Fig. 3). No significant changes were detected for p.S1096C and p.I1192V.  
Polymorphism p.A1151T also introduced a phosphorylation motif for several kinases (Fig. 3a), 
as GSK3, which phosphorylates Tau to produce amyloid-beta peptides in Alzheimer’s disease, is 
necessary for axon formation [33]. 
Although p.I1192 has been described to be pathogenic by Nichols and colleagues [34], no clear 
evidences for this association has yet been provided because diagnosis in some cases is unclear, and only 
two of the four affected members of the family who could be tested present this change. Besides, major 
changes were caused by polymorphisms p.R1067Q and p.L1165P (Table 1 and Suppl. Fig. 3), so 
perhaps these mutations should be studied further. 
ROC domain 
 The structure of this domain was solved by X-ray crystallography in 2008 (PDB ID 2zej) [11], 
and comprises six β-sheets and five α-helices. We modeled and analyzed the different substitutions 
described for ROC by homology using this structure as a template. This domain (Fig. 4a) is formed by 
five α-helices and six β-sheets that are linked by loops exposed to the solvent. Eight amino acid 
substitutions are described in this domain, and six are associated with PD; of those, three affect the same 
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residue, p.R1441. As shown in Fig. 4a, the three changes at this position implied loss of a positive charge 
and affected the domain surface. These mutations are on the dimerization surface and probably hinder this 
process. This amino acid is probably involved in forming hydrogen bonds between two monomers of 
LRRK2 to stabilize the dimer (Suppl. Fig. 4), as previously proposed [11]. Loss of p.R1441 implied the 
loss of these bonds with p.F1401 and p.T1404 at the other monomer. According to our results, the three 
mutations on R1441 had an effect on protein stability, whereas only p.R1441C/G affected the function 
and were predicted as pathogenic. However, the p.R1441H mutation had a drastic effect on the tertiary 
structure as it introduced torsion into this domain, and changed the inner and outer angles, as well as total 
domain length (Fig. 4b), and probably difficult dimerization, similarly to p.R1483Q, which was not 
described as pathogenic. p.I1371V and p.R1514Q had no apparent structural effects, but were predicted to 
cause stability changes (Table 1). According to our results, p.K1468E was predicted as functionally 
altered/pathogenic, and it changed the charge distribution (Table 1) and the electrostatic surface of this 
area (Fig. 4b). No significant changes were detected for p.A1442P. 
It is remarkable that almost all the substitutions described for this domain were associated with 
PD and that almost all of them were predicted to produce marked effects on the domain structure, stability 
or function, which were especially obvious for the mutations at position 1441. This demonstrates the 
importance of this domain in the function of this protein, if it affects its activity and/or binding of 
substrates, or if it affects the dimerization of the protein. 
COR domain 
 The structural model of this domain was performed by homology using the previously solved 
structure (PDB ID 3dpuA) as a template for the homologous domain in prokaryote C. tepidum [10]. 
According to this model, the domain is composed of nine α-helices and six β-sheets that are linked by 
loops exposed to the solvent (Fig. 4c). The N-terminal region contains six α-helices and two small β-
sheets, while the C-terminal region has three α-helices and four consecutive antiparallel β-sheets. The 
prediction for human COR differed primarily from the prokaryote homolog in its C-terminal half, an area 
responsible for dardarin dimerization in C. tepidum, thus supporting that in human dardarin, dimerization 
occurred through its ROC domain, as previously proposed [11]. For this domain, there were two PD-
related mutations, p.R1628P and p.Y1699C, and other six coding substitutions, two of them at position 
p.R1728. The models show that pathogenic mutation p.R1628P was predicted as such (Table 1), and that 
it drastically altered the secondary structure of the domain by abolishing the formation of two β-sheets 
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with, in addition, loss of a positive charge and changes in the electrostatic surface (Table 1 and Fig. 4c). 
Mutation p.Y1699C was also predicted as being functionally altered (Table 1), with a slightly altered 
electrostatic surface (Fig. 4c). Furthermore, p.R1725Q and p.R1728H affected stability, and the latter also 
affected the protein function. For these two changes, as well as for p.R1728L, the models reveal loss of a 
positive charge together with the alteration to the electrostatic surface (Table 1 and Fig. 4c). No 
significant changes were detected for p.V1613A and p.L1795F. 
 As in the ROC domain, almost all the substitutions described in the COR domain affected 
stability, function or structure (Table 1 and Fig. 4c). The reason why only p.R1628P and p.Y1699C were 
associated with PD could be that they are at the interface with the ROC domain, and could therefore 
affect the signal transduction between the GTPase and kinase domains [10]. This seems especially 
obvious for p.R1628P, which abolished the formation of two β-sheets and removed a positive charge in 
this area, which probably made the interactions and the domain structure especially difficult. 
 One mutation that has been recently described for this domain (p.S1761R) [35] presents a 
homolog residue in C. tepidum (S852). Previous results obtained with our model suggest that this 
mutation can affect dimerization through this domain [35]. 
KIN domain 
According to the model obtained (Suppl. Fig. 5a and Fig. 5), this domain is formed by seven α-
helices and six β-sheets linked by loops, which are exposed to the solvent. The structure model was 
performed by homology using the Roco4 kinase domain (PDB IDs 4f0f, 4fog, 4f1m and 4f1o), a protist 
homologous protein whose kinase domain was recently solved, [36] as a template. Six mutations have 
been broadly described in this catalytic domain: p.R1941H, p.Y2006H, p.I2012T, p.G2019S, p.I2020T 
and p.T2031S.  
The effect of amino acid substitution in the activation loop is particularly interesting as this loop 
regulates kinase activity. In fact, the most frequent mutation in PD, p.G2019S, is found in this loop, and 
has been demonstrated to give rise to enhanced kinase activity [37,14,38]. There are two plausible 
explanations for this; introducing a phosphorylation site (most of the mutations introduce an S or a T) or 
stabilizing active or inactive forms by hydrogen bonds [36]. Note that these possibilities are not exclusive, 
so the phosphate group could also alter the hydrogen bond distribution. In this work, we analyzed both 
possibilities. 
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The p.G2019 equivalent amino acid in the Dictyostelium discoideum Roco4 kinase domain has 
been proposed to introduce a hydrogen bond with p.R1918, which stabilizes the active form. This 
interaction cannot occur in the inactive form as amino acids are located too far away from each another 
[36]. We modeled the human domain using this structure as a template (Fig. 5) and also found an extra 
hydrogen bond in the active form (Fig. 5a), but with p.Q1919. The p.S2019 variant introduced an extra 
bond between itself and p.I2020, which could strengthen the polar contacts. p.T2031S substitution, which 
has been described to increase the active kinase form [38], also introduced an extra hydrogen bond, which 
could stabilize this form (Fig. 5a). In turn, p.I2020T formed an extra hydrogen bond, which could 
stabilize the inactive form (Fig.5b). Some authors have described this form as an equal [38] or an 
overactivated kinase [37], whereas other studies have described greater ATP-affinity and kinase activity 
in this variant [39]. 
The p.I2012T variant, near the catalytic loop, showed an extra hydrogen bond in both the active 
and inactive forms, but with different amino acids (Fig. 5c and 5d), which seemed to contribute to 
maintain conformation. In the active conformation, it bound to an amino acid of one helix involved in 
substrate recognition (Fig. 5c), while it bound to the same loop in inactive conformation (Fig. 5d). 
p.I2012T, p.G2019S and p.I2020T are suggested as being pathogenic and are in the activation 
loop of the kinase domain (Suppl. Fig. 5a), and they introduce or change phosphorylation motifs (Fig. 
3b). Thus, the p.I2012T mutation removed a putative phosphorylation motif for EGFR/Alk tyrosine 
kinases, but introduced a new motif for the PRKG1/MAP2K2 serine/threonine kinases. Otherwise, 
p.G2019S introduced new motifs for JAK3/BLK tyrosine kinase and PKA serine/threonine kinase. 
Finally, p.I2020T created target motifs for BLK tyrosine kinase and TAK1 serine/threonine kinase, 
without affecting the EGFR/Alk motif. The fact that the different mutations altered several recognition 
targets is particularly interesting if we consider that the activity of protein kinases is usually regulated by 
the phosphorylation of the activation loop, and that some of these mutations have been described as 
possessing increased kinase activity. Besides, p.T2031S, which is also in this loop, forms part of an 
autophosphorylation target motif  (Fig. 3b) that is also related with kinase activity regulation [40]. In fact, 
although T2031, S2032 and T2035 have been described as autophosphorylation motifs, and Ser-2032 and 
Thr-2035 are important sites that regulate LRRK2 kinase activity [40], our results suggest that they can be 
recognized by other important kinases (Fig. 3b). p.T2031S substitution changed a MAP3K motif for a 
MAP3K11 one, and removed a CK1/GRK1 phosphorylation site (S2032). p.Y2006H substitution also 
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altered the activation loop phosphorylation pattern by removing a tyrosine target of Fes kinase (Fig. 3b). 
Moreover in p.R1941H and p.Y2006H, the electrostatic surface was also altered (Suppl. Fig. 5a). 
Some structural and stability effects were observed in p.R1941H and p.Y2006H polymorphisms 
(Suppl. Fig. 5a and Table 1), which support the idea that they can be PD risk factors. 
WD40 domain 
According to the model obtained (Suppl Fig. 5b), this domain is formed by 30 β-sheets linked 
by loops exposed to the solvent to form a β-propeller. The model was run by threading and using mouse 
holoenzyme paf-ah (PDB ID 1vyhC) as a template. For this domain seven amino acid changes have been 
described, two of which have been suggested as being pathogenic (p.T2356I and p.G2385R), and the 
results indicate major changes for these mutations (Table 1). In addition, these mutations are located 
three-dimensionally near each other, indicating that their position can be especially important for the 
function as it alters the interaction with other proteins or ligands, as  proposed elsewhere [30]. Our results 
predict stability and electrostatic surface alterations for p.R2143H (Table 1 and Suppl. Fig. 5b), negative 
charge loss and electrostatic surface alteration for p.D2175H, and protein stability and polar contacts 
distribution alteration for p.T2356I; in the last case, stability affectations were probably due to loss of 
hydrogen bonds (Table 1 and Suppl. Fig. 5b). p. G2385R implied a gain of positive charge and 
electrostatic surface alterations due to the larger lateral chain size (Table 1 and Suppl. Fig. 5b). 
p.V2390M affected stability, whereas p.L2466H affected stability and function, also including a gain of a 
positive charge (Table 1). Finally, p.Y2189C and p.T2356I removed the Tyk2/JakA and MAPK2K/LKB 
motifs, respectively (Fig. 3a). 
Discussion 
One of the major challenges that the interpretation of genetic variants faces is translating the 
finding of a genetic substitution for a biologically sound mechanism that can link it with a given disorder. 
This is of particular interest when a gene is prone to show genetic variability that is not apparently 
associated with a disease caused by mutations in that same gene. This is the case of dardarin, which is 
responsible for familial forms of PD [2], but with a high degree of coding substitutions [41]. In line with 
this, we analyzed 20 amino acid substitutions that were reported to be pathogenic and 25 other coding 
substitutions that are allegedly polymorphisms. Usually, the pathogenicity of each new identified variant 
is predicted by taking into account its segregation in a particular pedigree, when it is found to be the result 
of genetic screening, when the phylogenetic conservation of the residue is affected and with the alteration 
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of functionally important residues when the protein function is known or can be inferred. We suggest that 
the molecular modeling of dardarin is a useful tool to predict the protein structure and the effect of 
missense substitutions to, therefore, contribute to assign a role in the pathogenicity of the molecule. Most 
of the mutations involved in PD, as well as many of the described polymorphisms, variably affect the 
secondary or tertiary structure, the electrostatic surface, hydrogen bonds, charge distribution, stability, the 
function or the phosphorylation sites involved in its regulation. The results of our analysis can also help to 
establish working hypotheses for future experiments. 
First, we define the domain boundaries based on predicted or previously resolved structures. The 
results obtained (Fig. 1) show the presence of an ARM domain (which has been controversial) and some 
differences with other works [5] in some domain definitions. Hence the COR and KIN domains are 54 
and 8 amino acids smaller than expected, respectively, whereas the LRR and ROC domains are 
respectively 5 and 2 amino acids bigger than previously described. These differences may well be 
important because they change the domain where polymorphism p.R1514Q is sited, which was usually 
sited in the COR domain and the ROC domain in our model (Fig. 2). 
Our results indicate different mechanisms of action for the mutations analyzed herein. First, 
through the alteration of protein-protein interaction domains, including dimerization; second, by the 
modification of phosphorylation motifs; third by structural alterations, including changes in the secondary 
or tertiary structure, polar contacts distribution, and modification of torsion and angles. 
Some substitutions produce major changes in the surface of the affected domains, which may be 
critical to determine the molecules with which dardarin can interact. This can explain, at least partially, 
the pathogenicity of mutations p.E334K (ARM), p.R793M (ANK), p.Q1111H (LRR) and p.G2385R 
(WD40) (Suppl. Fig. 2, Suppl. Fig. 3 and Suppl. Fig. 5b). The electrostatic potential of the surface, 
which is also important for the efficiency and stability of the interaction, also significantly altered in these 
mutants, except for p.G2385R. This alteration is not exclusive of pathogenic mutations as some 
polymorphisms, for example p.R1067Q and p.H1216R in the LRR domain or p.D2157H and p.R2143H 
in WD40, also produce an alteration on the electrostatic surface of the protein. This alteration would 
suggest that these polymorphisms act as genetic risk factors for the disease. 
With the ROC and COR domains, some major changes on the electrostatic surface were also 
detected for some mutations (p.R1441G/C/H and p.R1628P) and polymorphisms (p.K1468E and 
p.R1728H/L) (Fig. 4a and Fig. 4b). In these cases, pathogenicity can be explained by the role of the ROC 
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domain in the dimerization of dardarin (p.R1441) [11,10] or by the interaction with other molecules, such 
as GTP, for the ROC-GTPase domain.  
In addition, the phosphorylation pattern can be affected by amino acid changes, which thereby affect 
the functional regulation of the protein. Note that this protein is also related to the ERK/MKK pathways 
[1]. In some cases, the interaction (STE20 family) or the direct phosphorylation (PKC) by these kinases 
has been demonstrated [42]. 
No drastic structural changes were observed for the pathogenic mutations of the kinase domain 
(Table 1), although stability and function were predicted as being affected in most cases. It is noteworthy 
that these substitutions are in the activation loop, and that they introduce phosphorylatable residues, 
which alter the phosphorylation pattern of this loop (Table 1 and Fig. 3b), and whose phosphorylation is 
important for regulating kinase activity [43]. p.G2019S is in the conserved region DFG/DYG, so changes 
in the side chain of these positions can affect its activation, even though they do not affect the structure. 
In fact it has been postulated [44] that p.G2019S and p.I2020T provoke a conformational change that 
mimics the activated state, especially for p.G2019S, by abolishing the flexible nature of this conserved 
region by replacing glycine. We propose that this flexibility is affected by changes in the pattern of the 
polar bonds, so the p.S2019 variant establishes an extra hydrogen bond with p.I2020 (Fig. 5a). p.I2020T 
also forms an extra hydrogen bond, which can stabilize the inactive form (Fig. 5b), which could explain 
the decrease in kinase activity described previously [37]. The generation of an additional 
autophosphorylation site in the activation domain could also reinforce this increased activity [43]. In turn, 
p.I2012T introduces a phosphorylation target for PRKG1 and MAP2K2, and probably contributes to 
maintain the (active/inactive) conformation by polar contacts (Fig. 5c and Fig. 5d). In addition, p.G2019S 
removes a motif for EGFR/Alk, and introduces two new motifs for JAK3/BLK and PRKAR1A, whereas 
p.I2020T also introduces motifs for BLK and TAK1, but does not remove any EGFR/Alk site. Some of 
these kinases play key roles in the nervous system function and development. EGFR is involved in axon 
regeneration and neurite outgrowth [45], Alk in neuroblastoma development [46], Fes in axon guidance 
[47] and CDK1 in neuron degeneration [48]. p.T2031, p.S2032 and p.T2035 are auto-phosphorylation 
motifs in the activation loop [40], and they present phosphorylatable sequences by other kinases (Fig. 
3b). p.T2035 lies in a putative recognition site for several kinases that are important for the nervous 
system, such as GSK3 and CDK1 and DYRK1A,and is  involved in neuronal differentiation in response 
to nerve growth factor [49], which phosphorylates α-synuclein to facilitate its aggregation [50]. 
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Therefore, the non physiologic phosphorylation of mutant forms of dardarin by serin/threonin kinases, 
such as MAP2K2, PRKAR1A or MAP3K7, as well as changes in the autophosphorylation pattern (Fig. 
3), can explain the increased (p.G2019S and p.T2031S) or decreased (p.12012T and p.I2020T) kinase 
activity observed in these mutant forms [15,37,14,38].  
Some of the tested substitutions affect the number or distribution of polar contacts, which is the case 
of polymorphisms p.N363S (in the ARM domain, Suppl. Fig. 2a) and p.A1151T (LRR, Suppl. Fig. 3), 
or pathogenic mutations p.S1228T (LRR, Suppl. Fig. 5) and p.T2356I (WD40, Suppl. Fig. 5b). An 
alteration to these polar contacts can affect the stability or function of the protein (affected in most of 
these substitutions; Table 1), as well as the interaction with other domains or proteins. In fact at the ROC-
GTPase domain, p.R1441 mutations can also hinder the dimerization of LRRK2 in this way. As shown in 
Suppl. Fig. 4, p.R1441 forms hydrogen bonds with p.F1401 and p.T1404 of the other monomer, which 
probably does not occur in the mutants. In fact, the p.R1441H mutation probably involves the gain of a 
hydrogen bond within the monomer [43]. At the ROC domain, some dardarin auto-phosphorylation sites 
have also been identified [51], one in p.T1404, which postulates that phosphorylation at this position is 
required for phosphorylation of the p.T1491 residue involved in GTP binding and, therefore, in kinase 
activation. From this information, it can be hypothesized that position p.T1404 should be more accessible 
to phosphorylation through loss of the interaction with p.R1441. Therefore the substitutions at position 
p.R1441 can increase kinase activity through this mechanism.  
At the ROC domain some LRRK2 autophosphorylation sites have also been identified [51], one 
in p.T1404, which postulates that phosphorylation at this position is required for the phosphorylation of 
the p.T1491 residue involved in GTP binding and, therefore, in kinase activation. Based on this 
information, it can be hypothesized that position p.T1404 should be more accessible to phosphorylation 
through loss of the interaction with p.R1441, therefore the substitutions at position R1441 can enhance 
kinase activity through this mechanism.  
Liu and colleagues [52] used molecular modeling and docking, and proposed that the increased 
kinase activity seen for p.G2019S might be due to electrostatic alterations on the protein surface, which 
would result in substrate recognition alterations, but in a substrate-dependent way. Nevertheless for this 
mutation, it was not possible for us to detect any significant changes in electrostatic surface potential. 
This discrepancy might be related to specific effects given the substrate used by Liu and colleagues rather 
than to the effect that the mutation had. In a recent study [53], the same group described the effect of 
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p.G2019S substitution in kinase stabilization. Although these authors did not find any differences 
between the models they obtained with both templates, their results differ from ours in that the amino acid 
established the hydrogen bond with the p.S2019 variant. Along these lines, the differences we observed 
can be related to local discrepancies which might be lost when globally comparing the modeling obtained 
with the two templates used by these authors. In their model, the bond with p.G2019 was established with 
p.E1920, and with p.E1920 and p.Y2018 for p.S2019. In our model it was established with p.I2020, a 
residue that is also involved in PD, and with p.Q1919. These discrepancies can be due to the differences 
found in the templates used; whereas Liu and colleagues used B-raf kinase, we utilized Roco4 kinase. It is 
important to note that in the D. discoideum Roco4 kinase structure, p.R1077 (the equivalent to p.R1918 in 
human LRRK2) interacts only with the equivalent mutant form p.S1179 (p.S2019 in human), but not with 
the wild-type form p.G1179. For this reason, the role of this substitution in the stabilization of the active 
form in LRRK2 remains unclear. 
Moreover, although several polymorphisms have been described along LRRK2 with no association 
with PD, this analysis shows that many of them may affect the structure, stability or function. This can be 
explained if these polymorphisms are found in the protein regions not involved in those functions related 
to the binding of other substrates, catalytic activity or dimerization. Another possible reason is that the 
effect of these polymorphisms was compensated by the non mutated copy of the protein. Nonetheless, we 
must also consider the possibility that these mutations are involved in PD, but they exert a mild enough 
effect to not result in a significant change in the genetic risk for the disease. Association studies of 
polymorphisms in dardarin have proven the existence of significant differences in the penetrance of 
pathogenic mutations according to race, or even to the population analyzed [54]. This raised the 
possibility that some mutations with a pronounced effect on the protein, such as p.N363S (ARM), 
p.R793M (ANK), p.R1067Q (LRR) or p.R1728H/L (COR), may be related to PD in some populations, 
and perhaps in combination with other population-specific environmental and genetic factor. 
As expected, our analysis shows how the mutations that affect the enzymatic and the COR domains 
result in increased alterations on the structure, the stability or the function of these domains (Table 1, 
Suppl. Table 1 and Suppl. Table 2), thus confirming the key role of those domains in the function of the 
protein. 
It is also remarkable that many of the described mutations involve the loss or gain of an R residue 
(approximately one third); that is, the loss or gain of a positive charge. Besides the known importance of 
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the p.R1441 residue, the presence of conserved R residues on the surface of the LRR and WD40 domains, 
possibly involved in interactions with other proteins [5], can alter the specificity of binding to different 
proteins.  
Finally, it is noteworthy that some analyzed mutations can affect the interaction or relative position 
of the different domains among them. However, the size and complexity of this protein did not allow us 
to run a model for the entire protein, or even combinations of two or three domains, with acceptable 
results. For the same reason, we were unable to analyze the effect that a particular mutation might have 
on not only the domain where it appears, but also on adjacent domains, which could also prove important 
in the structure or for dimerization. 
The results obtained in this study reveal the usefulness of structural modeling and bioinformatics 
tools to predict the effects that mutations have on a protein. However, it is important to always take into 
account that these results are predictions based on mathematics and homology, and can help decide which 
are more suitable to, for example, generate experimental models in order to further investigate the 
etiology or treatment for a particular disorder. The determination of the real structural and functional 
effects of these mutations remains a goal to be reached in order to elucidate their role in the pathogenesis 
of PD. 
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Table 1. Summary of the effects of PD-related mutations in stability, function or 
structure of LRRK2 domains. Mutations described as pathogenic are marked by an 
asterisk. The columns “stability” and “pathogenicity/function” are the result of 
considering as good the predictions coincident of the 75% of the methods in Tables S1 y 
S2, respectively. The column “other alteration” is the result of the structural alterations 
or putative phosphorylation alterations detected. 
Domain Mutation Stability Path/Func Other alterations 
p.A211V    
p.E334K*   charge (-/+); electrostatic surface ARM 
p.N363S affected  phosphorylation; polar contacts 
p.M712V affected  electrostatic surface 
p.P755L*  affected  
p.R793M*   charge (+/º), electrostatic surface ANK 
p.I810V   electrostatic surface 
p.R1067Q affected  charge (+/-), electrostatic surface 
p.S1096C    
p.Q1111H* affected  electrostatic surface 
p.I1122V* affected   
p.A1151T   phosphorylation; polar contacts 
p.L1165P affected affected  
p.I1192V*    
p.H1216R   charge (º/+), electrostatic surface 
LRR 
p.S1228T* affected  phosphorylation; polar contacts 
p.I1371V* affected   
p.R1441C* affected affected dimerization; charge (+/º), electrostatic surface 
p.R1441G* affected affected dimerization; charge (+/º);electrostatic surface 
p.R1441H* affected  tertiary structure; dimerization;  charge (+/º);electrostatic surface 
p.A1442P*    
p.K1468E  affected charge (+/-), electrostatic surface 
p.R1483Q affected  tertiary structure; dimerization 
ROC  
p.R1514Q* affected   
p.V1613A    
p.R1628P*  affected secondary structure; charge (+/º), electrostatic surface 
p.Y1699C*  affected electrostatic surface 
p.R1725Q affected  charge (+/º), electrostatic surface 
p.R1728H affected affected electrostatic surface 
p.R1728L   charge (+/º), electrostatic surface 
p.L1795F    
COR 
p.Q1823K   charge (º/+), electrostatic surface 
p.R1941H  affected electrostatic surface 
p.Y2006H affected affected phosphorylation; electrostatic surface 
p.I2012T* affected affected phosphorylation 
p.G2019S*  affected phosphorylation 
p.I2020T* affected affected phosphorylation 
KIN 
p.T2031S   phosphorylation 
p.R2143H affected  electrostatic surface 
p.D2175H   charge (-/º), electrostatic surface 
p.Y2189C   phosphorylation 
p.T2356I* affected  phosphorylation;  polar contacts 
p.G2385R*  affected charge (º/+), electrostatic surface 
p.V2390M affected   
WD40 
p.L2466H affected affected  
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Fig. 1. Models and limit definition of the LRRK2 domains. The number of the first and last amino acid of 
the domain is shown in parentheses. Two views of the domain are shown, turned as indicated over the 
arrows. 
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Fig. 2. Distribution of the PD-related substitutions in relation to the functional domains of LRRK2. The 
mutations described as pathogenic are underlined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Effects of the PD-related mutations on the LRRK2 putative sequences for kinase recognition.  a) 
Alteration of kinase target sequences outside the kinase domain. b) Alteration of the kinase target 
sequence in the activation loop of the kinase domain. The sequences described as a substrate of auto-
phosphorylation are grouped by a bracket. Target sequences are underlined in order of appearance of 
kinase name (from left to right). The mutations described as pathogenic are underlined. The mutated 
amino acid is shown in gray. Sometimes the same sequence is a putative target of several kinases. 
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Fig. 4. Effects of PD-related mutations in the LRRK2 structural models. a) ROC domain structure and 
effects of p.R1441 substitutions on the electrostatic surface. b) Effects of p.R1441H, K1468E and 
p.R1483Q in electrostatic surface angles and distances of the ROC domain. c) The COR structure and 
effects of p.R1628P, affecting the secondary structure and the electrostatic surface; p.R1728H/L, 
affecting the electrostatic surface; and p.Y1699C, p.R1725Q and p.Q1823K, affecting the domain 
surface. The numbers over the arrow indicate the rotation of each axis used to obtain the figures. The 
numbers over the angles indicate the degrees (º), while the numbers under the lines indicate the distance 
(Å). 
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Fig. 5. Effects of the PD-related mutations on structural models of the LRRK2 kinase domain. a) Effect 
of p.G2019S, p.T2031S and p.I2012T on the polar contact distribution of the active form. b) Effect of 
p.I2020T and p.I2012T on the polar contact distribution of the inactive form. c) Effect of p.I2012T on the 
polar contact distribution of the active form. d) Effect of p.I2012T on the polar contact distribution of the 
inactive form. The numbers over the arrow indicate the rotation of each axis used to obtain the figures. 
Hydrogen bonds are illustrated with dotted lines. 
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Suppl. Fig. 1. Details of the templates used for modeling LRRK2 domains. The alignment of the LRRK2 
sequences with the templates without gaps and modeling parameters are shown. For homology modeling 
is indicated the % of identity, whereas for threading modeling are listed the program used, coverage, 
sequence identity, z-score and confidence. 
c) LRR domain: identity = 30%
a) ARM domain. Program HH Search V.1.5b; coverage=0.692; sequence identity=0.135; z-score=44.88; high confidence
b) ANK domain. Program SPARKS2; coverage=0.976; sequence identity=0.172; z-score=21.57; high confidence
d) COR domain: identity = 26%
e) KIN domain: identity = 28%
f) WD40 domain. Program SP3; coverage=0.976; sequence identity=0.172; z-score=21.54; high confidence
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suppl. Fig. 2. Effects of PD-related mutations in LRRK2 structural models. a) ARM structure and effects 
of p.E334K and p.N363S in electrostatic surface and polar contacts distribution, respectively. b) ANK 
domain and effects of p.R793M in electrostatic surface and effects of p.M712V and p.I810V in the 
surface of the domain. The numbers over the arrow indicate the rotation of each axis used to show the 
figures. Mutations described as pathogenic are underlined. 
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Suppl. Fig. 3. Effects of PD-related mutations in LRR domain structural model. The figure shows the 
effects p.R1067Q, p.Q1111H and p.H1216R in the electrostatic surface and of p.A1151T and p.S1228T 
in polar contacts distribution. The numbers over the arrow indicate the rotation of each axis used to show 
the figures. Mutations described as pathogenic are underlined. 
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Suppl. Fig. 4. Effects of substitution of R1441 on polar contacts involved in LRRK2 dimers stabilization. 
Substitution of R1441 affect to the polar contacts with F1401, T1404 of the other monomer of LRRK2. 
This figure was obtained using the structure previously solved. 
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Suppl. Fig. 5. Effects of PD-related mutations in LRRK2 structural models. a) KIN domain structure and 
effects of p.R1941H in electrostatic surface and p.Y2006H in the surface of the domain. Subdomains 
important for the kinase activity are indicated in the figure. b) WD40 structure and effects of p.R2143H 
and p.T2356I, affecting electrostatic surface and polar contact distribution, respectively; and effects of 
p.D2175H and p.G2385R in the surface of the domain. The numbers over the arrow indicate the rotation 
of each axis used to show the figures. Mutations described as pathogenic are underlined. 
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Supplementary Table 1. Prediction of effects of amino acid substitution in protein stability. Stability of 
was predicted using four methods, and parameters obtained are showed. Pathogenic mutations are marked 
by *. For the elaboration of Table 1, only results coincident in at least 75% of the methods were taken 
into account (in bold). 
I-Mutant  MuPro  Eris MuStab  
Mutation 
DDG RI Stability CS1 CS2 Stability DDG Pred Conf 
p.A211V -0.27 1  0.17 -0.63  -6,04 Increase 24.6 
p.E334K* -0.66 4 Decrease -0.48 -0.81 Decrease -3,51 Increase 31.8 
p.N363S 0.22 1  -1 -0.88 Decrease -2,27 Decrease 93 
p.M712V -1.04 9 Decrease -0.31 -0.85 Decrease -7,85 Decrease 85.9 
p.P755L* -0.72 4 Decrease -0.48 -0.66 Decrease -1,55 Decrease 85.5 
p.R793M* -0.95 4 Decrease 0.46 0.67 Increase -5,45 Decrease 79.6 
p.I810V -0.66 8 Decrease -1 -0.98 Decrease -1,27 Decrease 90.2 
p.R1067Q -2.16 9 Decrease -0.69 -0.61 Decrease 1,92 Decrease 90.7 
p.S1096C -0.70 2 Decrease -0.29 -0.69 Decrease 6,38 Decrease 92.8 
p.Q1111H* -1.09 7 Decrease -1 -0.72 Decrease -2,75 Decrease 79.8 
p.I1122V* -0.06 6 Decrease -1 -0.91 Decrease 5,49 Decrease 93.7 
p.A1151T 0.61 7 Decrease -0.51 -0.58 Decrease 0,35 Decrease 88 
p.L1165P -0.78 7 Decrease -1  Decrease 2,31 Decrease 90.7 
p.I1192V* -0.03 6 Decrease -1 -0.89 Decrease -0,53 Decrease 83.7 
p.H1216R -0.06 4  -0.08 -0.87 Decrease -0,14 Decrease 82.1 
p.S1228T* -1.08 2 Decrease -0.27 -0.75 Decrease 5,14 Decrease 93.7 
p.I1371V* -1.48 9 Decrease -1 -0.91 Decrease -0,99 Decrease 92.7 
p.R1441C* -2.02 9 Decrease -0.64 -0.85 Decrease -0,68 Decrease 82.1 
p.R1441G* -1.30 6 Decrease -1 -0.99 Decrease 0,08 Decrease 92.9 
p.R1441H* -1.97 9 Decrease -1 -0.99 Decrease 0,59 Decrease 81 
p.A1442P* -0.34 3 Decrease -0.06 -0.52 Decrease 1,99 Increase 23.2 
p.K1468E 0.18 0 Decrease -0.43  Decrease -1,56 Decrease 81.2 
p.R1483Q -1.38 9 Decrease -0.92  Decrease -0,04 Decrease 89.6 
p.R1514Q* -1.35 9 Decrease -1 0.71 Decrease -2,42 Decrease 92.5 
p.V1613A -0.93 9 Decrease -1 -0.99 Decrease -8,82 Decrease 92.3 
p.R1628P* -2.24 7 Decrease -0.23 -0.55 Decrease 7,99 Decrease 83 
p.Y1699C* -0.79 1 Decrease -0.78 -0.59 Decrease -12,5 Decrease 91.8 
p.R1725Q -1.26 8 Decrease -0.04   -2,42 Decrease 81 
p.R1728H -0.41 8 Decrease -0.81 -0.89 Decrease -9,74 Decrease 81.2 
p.R1728L 0 5 Decrease 0.67 -0.63 Decrease -0,37 Decrease 82.7 
p.L1795F -0.01 8 Decrease -1 -0.98 Decrease -1,53 Decrease 87.9 
p.Q1823K -0.32 1 Increase 0.03   -7,85 Decrease 80.5 
p.R1941H -1.21 8 Decrease -0.18 -0.89 Decrease -1,28 Decrease 78.6 
p.Y2006H -0.39 5 Decrease -1 -0.99 Decrease -3,34 Decrease 81.6 
p.I2012T* -1.91 9 Decrease -1 -0.90 Decrease -2,78 Decrease 94.1 
p.G2019S* -0.98 8 Decrease -1 -0.92 Decrease -1,83 Increase 26.2 
p.I2020T* -2.31 9 Decrease -1 -0.91 Decrease 2,76 Decrease 94.8 
p.T2031S 0.02 4  -0.31 -0.68 Decrease -4,27 Decrease 93.4 
p.R2143H -1.58 9 Decrease -0.07 -0.72 Decrease -2.41 Decrease 81.6 
p.D2175H -0.2 3 Decrease -0.61   >10 Decrease 28.6 
p.Y2189C -0.72 2 Decrease -0.51   >10 Decrease 87.3 
p.T2356I* -0.4 1  -1 -0.86 Decrease -5.23 Decrease 79.8 
p.G2385R* -1.61 8 Decrease -0.08 -0.5 Decrease >10 Increase 22.8 
p.V2390M -0.61 8 Decrease -1  Decrease 6.90 Decrease 92.5 
p.L2466H -2.33 8 Decrease -0.96 -0,98 Decrease 7.47 Decrease 89.6 
Supplementary Table 2. Prediction of pathogenicity of amino acid substitution. Pathogenicity was 
predicted using five methods, and parameters obtained are showed. Pathogenic mutations are marked by 
*. For the elaboration of Table 1, only results coincident in at least 75% of the methods were taken into 
account (in bold). DI=dissimilarity index 
SIFT  PolyPhen  Pmut  PhD-SNP  
Mutation DI  
Score Funct Prediction 
PSIC 
Score 
NN R Prediction Effect R 
p.A211V 1.22 0.03 affect  1.61 0.16 6   8 
p.E334K*
 1.99 0.00 affect  1.26 0.33 3   6 
p.N363S 0.37   poss damag 1.51 0.13 7   7 
p.M712V 0.81 0.00 affect poss damag 1.51 0.29 4   6 
p.P755L* 1.94 0.01 affect prob damag 2.55 0.49 0   4 
p.R793M* 1.80 0.05 affect poss damag 1.58 0.34 3   7 
p.I810V 0.56 0.01 afect  0.9 0.04 9   7 
p.R1067Q 2.03 0.00 afect  1.36 0.15 6   7 
p.S1096C 0.55 0.01 afect  1.46 0.30 3  disease 6 
p.Q1111H* 0.43 0.03 afect poss damag 1.7 0.05 9   2 
p.I1122V* 0.56    0.92 0.04 9   8 
p.A1151T 1.12    1.17 0.09 8   3 
p.L1165P 1.94   poss damag 1.93 0.71 4 Patholog disease 8 
p.I1192V* 0.56    0.71 0.04 9   6 
p.H1216R 1.79   prob damag 2.30 0.34 3   5 
p.S1228T* 0.13 0.03 afect  1.20 0.04 9   7 
p.I1371V* 0.56 0.02 afect  0.71 0.05 8   4 
p.R1441C* 3.39   poss damag 1.89 0.83 6 Patholog  4 
p.R1441G* 1.50   poss damag 1.78 0.63 2 Patholog  0 
p.R1441H* 1.79   poss damage 1.69 0.31 3   0 
p.A1442P* 0.56 0.04 affect  1.45 0.45 0  disease 2 
p.K1468E 1.99 0.00 affect 
poss damag 
struct effect 
1.27 0.27 4   6 
p.R1483Q 2.03    1.35 0.14 7   7 
p.R1514Q* 2.03    0.19 0.14 7   9 
p.V1613A 1.22 0.01 affect  1.37 0.23 5   9 
p.R1628P* 0.76 0.03 affect prob damag 2.03 0.75 5 Patholog disease 8 
p.Y1699C* 1.25 0.01 affect prob damag 2.40 0.77 5 Patholog  0 
p.R1725Q 2.03 0.04 affect  1.38 0.14 7   0 
p.R1728H 1.79 0.02 affect poss damag 1.58 0.31 3   5 
p.R1728L 0.73   prob damag 2.03 0.63 2 Patholog  8 
p.L1795F 0.74 0.02 affect  1.24 0.20 6   7 
p.Q1823K 0.69   poss damag 1.52 0.14 7   7 
p.R1941H 1.79   poss damag 1.69 0.31 3  disease 7 
p.Y2006H 0.93 0.00 affect poss damag 1.61 0.09 8  disease 1 
p.I2012T* 0.49 0.02 affect poss damag 1.61 0.42 1  disease 1 
p.G2019S* 1.53 0.00 affect poss damag 1.58 0.28 4  disease 7 
p.I2020T* 0.49 0.01 affect poss damag 1.61 0.42 1  disease 8 
p.T2031S 0.13 0.00 affect  0.36 0.05 9   7 
p.R2143H 1.79    0.65 0.31 3   0 
p.D2175H 1.05    1.12 0.61 2 Patholog   
p.Y2189C 1.25    1.94 0.77 5 Patholog   
p.T2356I* 0.49 0.05 affect  0.45 0.42 1   1 
p.G2385R* 1.50 0.00 affect  0.10 0.60 1 Patholog  2 
p.V2390M 0.81 0.02 affect  1.19 0.13 7   6 
p.L2466H 0.63 0.01 affect poss damag 1.72 0.75 4 Patholog  3 
 
